These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15938760)

  • 1. The phosphoinositide 3-kinase pathway and cancer.
    Stokoe D
    Expert Rev Mol Med; 2005 Jun; 7(10):1-22. PubMed ID: 15938760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic kinase signalling.
    Blume-Jensen P; Hunter T
    Nature; 2001 May; 411(6835):355-65. PubMed ID: 11357143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma.
    Jacob A; Lee TX; Neff BA; Miller S; Welling B; Chang LS
    Otol Neurotol; 2008 Jan; 29(1):58-68. PubMed ID: 18199958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
    Olsen BB; Bjørling-Poulsen M; Guerra B
    Int J Biochem Cell Biol; 2007; 39(1):227-37. PubMed ID: 17018259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
    Granville CA; Memmott RM; Gills JJ; Dennis PA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):679-89. PubMed ID: 16467077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3 kinases in cancer: from oncogene artifact to leading cancer target.
    Zhao JJ; Roberts TM
    Sci STKE; 2006 Dec; 2006(365):pe52. PubMed ID: 17164467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
    Wee S; Lengauer C; Wiederschain D
    Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
    Georgakis GV; Younes A
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
    Prasad R; Giri S; Nath N; Singh I; Singh AK
    J Neurochem; 2005 Jul; 94(1):204-14. PubMed ID: 15953363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target.
    Goswami A; Ranganathan P; Rangnekar VM
    Cancer Res; 2006 Mar; 66(6):2889-92. PubMed ID: 16540633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
    Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular network of phosphatidylinositol 3-kinase, mammalian target of the rapamycin/70 kDa ribosomal S6 kinase 1, and mitogen-activated protein kinases pathways for regulating mycobacteria-induced IL-23 expression in human macrophages.
    Yang CS; Song CH; Lee JS; Jung SB; Oh JH; Park J; Kim HJ; Park JK; Paik TH; Jo EK
    Cell Microbiol; 2006 Jul; 8(7):1158-71. PubMed ID: 16819968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR, translation initiation and cancer.
    Mamane Y; Petroulakis E; LeBacquer O; Sonenberg N
    Oncogene; 2006 Oct; 25(48):6416-22. PubMed ID: 17041626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway.
    Ram R; Uziel O; Eldan O; Fenig E; Beery E; Lichtenberg S; Nordenberg Y; Lahav M
    Clin Cancer Res; 2009 Feb; 15(3):914-23. PubMed ID: 19188162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of lymphocyte function associated antigen 1 by LFA878 induces apoptosis in multiple myeloma cells and is associated with downregulation of the focal adhesion kinase/phosphatidylinositol 3 kinase/Akt pathway.
    Schmidmaier R; Mandl-Weber S; Gaul L; Baumann P; Bumeder I; Straka C; Emmerich B
    Int J Oncol; 2007 Oct; 31(4):969-76. PubMed ID: 17786331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive diffuse activation of phosphoinositide 3-kinase at the plasma membrane by v-Src suppresses the chemotactic response to PDGF by abrogating the polarity of PDGF receptor signalling.
    Platek A; Vassilev VS; de Diesbach P; Tyteca D; Mettlen M; Courtoy PJ
    Exp Cell Res; 2007 Apr; 313(6):1090-105. PubMed ID: 17335807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
    Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
    Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R; Melisi D; Ciardiello F; Tortora G
    Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.